Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
4 lessons
9mMost peptide stigma is not a single hazard. It is three different risks that clinics mash together. Separate them and the conversation with counsel, pharmacy, and medical directors gets shorter.
9mPemvidutide is interesting because it does not just ask whether body weight falls. It asks whether liver fat, waist size, appetite, and recovery move together in a clean direction.
9mTesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mRetatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
Also available at /blog for legacy links.